[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"thrombosis-embolism\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:thrombosis-embolism":65},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,41],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100546348",false,"NCT06393764","Cancer-related Venous Thromboembolic Disease - Cohort Study","Establishment of a Patient-based Cohort : Cancer-related Venous Thromboembolic Disease.","CAPE","Inclusion Criteria:\n\n* Patients aged 18 years and more.\n* Patients with active cancer or requiring cancer treatment at the time of their VTE episode\n* Patients with documented VTE less than 2 years old\n* Patients affiliated to the social security system\n* Patient who has signed a written informed consent\n\nExclusion Criteria:\n\n* Patient under 18\n* Refusal to participate\n* Incapacity to consent to the study\n* Patient under guardianship\n* Incapacity to communicate (comprehension disorder)\n* Life expectancy of less than 6 months","ALL","18 Years","80 Years",{"count":20,"type":21},150,"ESTIMATED","OBSERVATIONAL","Venous thromboembolic disease (VTE) is a common (1\u002F1000), potentially serious disease (10% mortality when the clinical presentation is that of pulmonary embolism (PE)). In cancer patients, the risk of developing VTE is high and constitutes a negative prognostic factor for cancer; the risk of bleeding is also increased. The study of VTE in the context of cancer is a major challenge, given the frequency of the association, the heterogeneity of the situations, the risk factors involved and the therapeutic issues in both curative and primary prevention; in this field, many uncertainties remain, justifying a study focused on the association of VTE and cancer.",[25,26,27],"Thrombosis Embolism","Thromboses, Venous","Cancer","RECRUITING","2026-06-12",{"date":31,"type":32},"2026-06-15","ACTUAL",{"date":34,"type":32},"2025-10-30",{"date":36,"type":21},"2035-10",{"name":38,"class":39},"University Hospital, Brest","OTHER",1,{"id":42,"slug":4,"hasResults":10,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":48,"targetDuration":50,"studyType":22,"phases":4,"briefSummary":51,"conditions":52,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":40},"100353396","NCT03881345","Ongoing Registry of Treatment of Venous Thromboembolism","Russian Registry of Treatment of Venous Thromboembolism","RRT VTE","Inclusion Criteria:\n\n* case of venous thrombosis of a limb or pulmonary embolus\n\nExclusion Criteria:\n\n* no exclusion criteria",{"count":49,"type":21},5000,"12 Months","Ongoing registration of patients with venous thromboembolism treated by means of antithrombotic therapy, thrombolisys, open surgery, endovenous desobstruction and stenting.",[53,26,25,54,55],"Deep Vein Thrombosis","Postthrombotic Syndrome","Pulmonary Embolism","2025-05-05",{"date":58,"type":32},"2025-05-08",{"date":60,"type":32},"2019-04-01",{"date":62,"type":21},"2036-03-01",{"name":64,"class":39},"Medalp Private Surgery Clinic",""]